Innate Pharma’s (IPHA) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Innate Pharma (NASDAQ:IPHA) in a research note issued to investors on Thursday,Benzinga reports. BTIG Research currently has a $9.00 price target on the stock.

A number of other analysts also recently weighed in on IPHA. Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 target price on the stock in a research report on Tuesday, August 11th. HC Wainwright lifted their price target on shares of Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, August 10th. UBS Group reissued a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.67.

Innate Pharma Trading Down 0.5%

IPHA opened at $1.90 on Thursday. The stock has a fifty day simple moving average of $1.98 and a two-hundred day simple moving average of $1.74. Innate Pharma has a 12-month low of $1.17 and a 12-month high of $2.71.

Key Stories Impacting Innate Pharma

Here are the key news stories impacting Innate Pharma this week:

• Positive Sentiment: Innate Pharma reported second-quarter EPS of -$0.12, better than the consensus estimate of -$0.29. The improvement in profitability and narrower first-half loss may support sentiment by indicating tighter cost control. Innate Pharma earnings report
• Positive Sentiment: The company said its partnership with Sobi is now effective after all closing conditions were completed. The agreement strengthens development and commercialization support for Innate’s programs, including lacutamab. Sobi and Innate partnership announcement
• Positive Sentiment: Innate highlighted continued advancement of lacutamab and IPH4502, offering investors additional clinical-development catalysts. Management discussed the progress during the second-quarter earnings call. Innate Pharma Q2 2026 earnings call transcript
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and assigned a $9.00 price target, signaling substantial upside in the analyst’s valuation based on the company’s pipeline and partnership prospects. BTIG rating report
• Negative Sentiment: Quarterly revenue was $3.23 million, below the approximately $6.35 million analyst consensus. The revenue shortfall could temper the benefit of the EPS beat and keep attention focused on financing needs and clinical execution. Innate Pharma first-half results

Innate Pharma Company Profile

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.